The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2019

Filed:

May. 02, 2018
Applicant:

The Scripps Research Institute, La Jolla, CA (US);

Inventor:

Matthew D. Disney, Jupiter, FL (US);

Assignee:

The Scripps Research Institute, La Jolla, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/40 (2006.01); C12N 15/63 (2006.01); A61K 31/404 (2006.01); C07D 471/04 (2006.01); C07D 209/14 (2006.01); C07D 209/42 (2006.01); A61K 31/7105 (2006.01); C07H 21/02 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/63 (2013.01); A61K 31/404 (2013.01); A61K 31/7105 (2013.01); C07D 209/14 (2013.01); C07D 209/42 (2013.01); C07D 471/04 (2013.01); C07H 21/02 (2013.01); C12N 15/113 (2013.01); A61K 38/00 (2013.01); A61K 48/00 (2013.01); C12N 2310/14 (2013.01);
Abstract

A repeat expansion in C9ORF72 causes frontotemporal dementia and amyotrophic lateral sclerosis (c9FTD/ALS). RNA of the expanded repeat (r(GGGGCC)) forms nuclear foci or undergoes repeat-associated non-ATG (RAN) translation producing 'c9RAN proteins'. Since neutralizing r(GGGGCC)could inhibit these potentially toxic events, we sought to identify small molecule binders of r(GGGGCC). Chemical and enzymatic probing of r(GGGGCC)indicate it adopts a hairpin structure in equilibrium with a quadruplex structure. Using this model, bioactive small molecules targeting r(GGGGCC)were designed and found to significantly inhibit RAN translation and foci formation in cultured cells expressing r(GGGGCC)and neurons trans-differentiated from fibroblasts of repeat expansion carriers. Finally, we show that poly(GP) c9RAN proteins are specifically detected in c9ALS patient cerebrospinal fluid. Our findings highlight r(GGGGCC)-binding small molecules as a possible c9FTD/ALS therapeutic, and suggest c9RAN proteins could potentially serve as a pharmacodynamic biomarker to assess efficacy of therapies that target r(GGGGCC).


Find Patent Forward Citations

Loading…